Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System

A dysregulated immune response with hyperinflammation is observed in patients with severe coronavirus disease 2019 (COVID-19). The aim of the present study was to assess the safety and potential benefits of human recombinant C1 esterase inhibitor (conestat alfa), a complement, contact activation and...

Descripción completa

Detalles Bibliográficos
Autores principales: Urwyler, Pascal, Moser, Stephan, Charitos, Panteleimon, Heijnen, Ingmar A. F. M., Rudin, Melanie, Sommer, Gregor, Giannetti, Bruno M., Bassetti, Stefano, Sendi, Parham, Trendelenburg, Marten, Osthoff, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456998/
https://www.ncbi.nlm.nih.gov/pubmed/32922409
http://dx.doi.org/10.3389/fimmu.2020.02072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456998/
https://www.ncbi.nlm.nih.gov/pubmed/32922409
http://dx.doi.org/10.3389/fimmu.2020.02072

Ejemplares similares